reports
- Tushar Manudhane
MOSL: . CIPLA: Pipeline build-up on track in the Respiratory and Pept...
One-India strategy driving steady industry outperformance CIPLA delivered a better-than-expected 1QFY23 performance, led by healthy traction in the US and emerging markets, and controlled cost. The strategy of ‘One-India’ (prescription, trade generics, and consumer health) as well as building a Complex Respiratory and Peptide pipeline in the US Generics is progressing well to cater to better business prospects over the next three-to-five years. We tweak our FY23/FY24 estimate by +3%/+2%, fac...
- MarketLine Department
Glenmark Pharmaceuticals Limited - Mergers & Acquisitions (M&A), Partn...
Summary Marketline's Glenmark Pharmaceuticals Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Glenmark Pharmaceuticals Limited since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.